Overview
BiotechPhase 1ibogainepsilocybinDMT
Formed in November 2025 from the combination of atai Life Sciences and Beckley Psytech. Acquired by Eli Lilly in July 2026 for about $2.8 billion upfront (up to $3.8 billion), led by its intranasal 5-MeO-DMT candidate BPL-003 for treatment-resistant depression. Now operates as part of Eli Lilly.
Visit WebsiteBerlin, Germany
3
Clinical Trials
2018
Founded
120
Employees
0
Open Roles
Open Positions
No open positions at this time
Clinical Pipeline(3)
Completed·Phase 1·ibogaine
A Study of Oral Ibogaine in Opioid Withdrawal
DMX-1002Opiate Withdrawal Syndrome
Terminated·Phase 1·psilocybin
Phase 1b Study in Patients With Short-Lasting Unilateral Neuralgiform Headache Attacks (SUNHA)
PsilocybinShort Lasting Unilateral Neuralgiform Headache Attacks
Completed·Phase 1·DMT
Single Ascending Dose Study With 5-MeO-DMT in Healthy Subjects
5-MeO-DMTPharmacokinetics in Healthy Adults